AU2020276213A1 - Methods for improving the quality of life of a patient with a peanut allergy - Google Patents

Methods for improving the quality of life of a patient with a peanut allergy Download PDF

Info

Publication number
AU2020276213A1
AU2020276213A1 AU2020276213A AU2020276213A AU2020276213A1 AU 2020276213 A1 AU2020276213 A1 AU 2020276213A1 AU 2020276213 A AU2020276213 A AU 2020276213A AU 2020276213 A AU2020276213 A AU 2020276213A AU 2020276213 A1 AU2020276213 A1 AU 2020276213A1
Authority
AU
Australia
Prior art keywords
patient
peanut
oral immunotherapy
administered
life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020276213A
Other languages
English (en)
Inventor
Christine BIRCHWOOD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2020276213A1 publication Critical patent/AU2020276213A1/en
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. Request for Assignment Assignors: AIMMUNE THERAPEUTICS, INC.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2020276213A 2019-05-10 2020-05-08 Methods for improving the quality of life of a patient with a peanut allergy Pending AU2020276213A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962846481P 2019-05-10 2019-05-10
US62/846,481 2019-05-10
US201962855384P 2019-05-31 2019-05-31
US62/855,384 2019-05-31
US202062967948P 2020-01-30 2020-01-30
US62/967,948 2020-01-30
PCT/US2020/032179 WO2020231843A1 (en) 2019-05-10 2020-05-08 Methods for improving the quality of life of a patient with a peanut allergy

Publications (1)

Publication Number Publication Date
AU2020276213A1 true AU2020276213A1 (en) 2021-10-28

Family

ID=73289227

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020276213A Pending AU2020276213A1 (en) 2019-05-10 2020-05-08 Methods for improving the quality of life of a patient with a peanut allergy

Country Status (7)

Country Link
US (2) US11229673B2 (https=)
EP (1) EP3965815A4 (https=)
JP (1) JP7574222B2 (https=)
CN (1) CN113966229A (https=)
AU (1) AU2020276213A1 (https=)
CA (1) CA3137295A1 (https=)
WO (1) WO2020231843A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
WO2022003604A1 (en) 2020-07-01 2022-01-06 Société des Produits Nestlé S. A. Determining medical staffing for oral immunotherapy
KR20230148769A (ko) 2022-04-15 2023-10-25 사회복지법인 삼성생명공익재단 경구면역요법을 이용한 식품알레르기 치료서비스 제공방법, 이를 구현하기 위한 기록매체에 저장된 컴퓨터 프로그램 및 시스템

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
AU2065801A (en) 1999-12-06 2001-06-12 Panacea Pharmaceuticals, Llc Passive desensitization
AU1951001A (en) 2000-04-06 2001-09-17 Panacea Pharm Llc Microbial delivery system
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
EP1599185A1 (en) 2003-02-28 2005-11-30 Alk-Abello A/S Dosage form having a saccharide matrix
EP1734975B1 (en) 2004-03-19 2015-06-10 Herbs Spring, LLC Herbal therapy for the treatment of food allergy
WO2005100995A2 (en) 2004-04-06 2005-10-27 Mount Sinai School Of Medicine Methods of determining allergen response using microarray imminoassay techinques
BRPI0520821A2 (pt) 2005-12-28 2009-06-30 Teva Pharma formulações farmacêuticas de fenofibrato com biodisponibilidade melhorada
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
HRP20200284T1 (hr) 2008-10-02 2020-07-10 Salix Pharmaceuticals, Ltd. Postupci liječenja hepatičke encefalopatije
BRPI0921507A2 (pt) 2008-11-19 2016-01-19 Avantor Performance Mat Inc composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo
US8399519B2 (en) 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
GB201104537D0 (en) * 2011-03-17 2011-05-04 Cambridge Entpr Ltd Treatment for peanut allergy
US20140207105A1 (en) 2011-08-31 2014-07-24 Perosphere, Inc. Methods for Effectively and Rapidly Desensitizing Allergic Patients
WO2013087119A1 (en) 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
CN104080465A (zh) 2012-01-13 2014-10-01 科.汉森有限公司 用于预防或治疗上呼吸道感染的鼠李糖乳杆菌和动物双歧杆菌乳亚种
CN109125283A (zh) 2013-03-14 2019-01-04 艾慕恩治疗公司 用于口服脱敏的花生制剂的制备
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
KR102233251B1 (ko) 2013-04-03 2021-03-26 엔-폴드 엘엘씨 신규 나노입자 조성물
US9456628B2 (en) 2013-06-13 2016-10-04 D&E Gillespie Enterpries LLC Methods and products to provide oral nutritional care to subjects with dementia
US20150343075A1 (en) 2014-06-02 2015-12-03 Aimmune Therapeutics Placebo formulations and uses thereof
EP3185900A4 (en) 2014-08-25 2018-05-02 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
GEAP201814459A (en) 2014-09-04 2018-09-10 Helsinn Healthcare Sa Medical treatments based on anamorelin
UA122670C2 (uk) 2014-09-08 2020-12-28 Сефалон, Інк. Спосіб лікування еозинофільної астми у пацієнта
JP2020514306A (ja) 2017-01-13 2020-05-21 アイミューン セラピューティクス，インコーポレイテッド 経口免疫療法用のナッツ粉および製剤の製造方法
FR3062797B1 (fr) * 2017-02-10 2025-03-07 Centre Hospitalier Et Univ De Clermont Ferrand Gelule a liberation gastro-intestinale destinee a etre utilisee dans une methode permettant de desensibiliser et/ou d'induire une tolerance chez un sujet allergique a l'arachide
US11369676B2 (en) * 2017-11-02 2022-06-28 Société des Produits Nestlé S.A. Methods of oral immunotherapy
USD866321S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
EP3829632A4 (en) 2018-07-27 2022-05-04 Société des Produits Nestlé S.A. SYSTEMS AND METHODS FOR DELIVERING UNIT DOSES OF ORAL IMMUNOTHERAPY
USD866322S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Medicine folio
USD866320S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
US12433945B2 (en) * 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401576A1 (en) 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
US12226448B2 (en) 2018-12-20 2025-02-18 Société des Produits Nestlé S.A. Peanut oral immunotherapy dosing schedule for missed doses
EP3942299A4 (en) 2019-03-22 2023-06-28 Société des Produits Nestlé S.A. Systemic allergic response risk assessment in peanut oral immunotherapy
WO2020237181A1 (en) 2019-05-23 2020-11-26 Aimmune Therapeutics, Inc. Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance

Also Published As

Publication number Publication date
US20230090380A1 (en) 2023-03-23
CN113966229A (zh) 2022-01-21
EP3965815A1 (en) 2022-03-16
US20200368304A1 (en) 2020-11-26
US11229673B2 (en) 2022-01-25
JP2022532547A (ja) 2022-07-15
CA3137295A1 (en) 2020-11-19
WO2020231843A1 (en) 2020-11-19
JP7574222B2 (ja) 2024-10-28
EP3965815A4 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
US20230090380A1 (en) Methods for improving the quality of life of a patient with a peanut allergy
Wasserman et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients
JP7498661B2 (ja) 経口免疫療法の方法
Hummel et al. Primary dietary intervention study to reduce the risk of islet autoimmunity in children at increased risk for type 1 diabetes: the BABYDIET study
Buchanan et al. Egg oral immunotherapy in nonanaphylactic children with egg allergy
Greiwe et al. AAAAI work group report: trends in oral food challenge practices among allergists in the United States
JP7536035B2 (ja) ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
Upton et al. Oral food challenges: Special considerations
Dunn Galvin et al. Psychosocial mediators of change and patient selection factors in oral immunotherapy trials
Kredlow et al. Exploring the boundaries of post-retrieval extinction in healthy and anxious individuals
WO2020237181A1 (en) Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance
Rodríguez del Río et al. Evaluation of clinical outcomes of efficacy in food allergen immunotherapy trials, COFAITH EAACI task force
Scurlock et al. Advances in the approach to the patient with food allergy
Brown-Whitehorn et al. Sustained unresponsiveness to peanut after long-term peanut epicutaneous immunotherapy
Yahia et al. Oral immunotherapy for children with a high-threshold peanut allergy
Huber et al. Attentional and emotional mechanisms of pain processing and their related factors: a structural equations approach
Swerdlow et al. Auditory discrimination and frequency modulation learning in schizophrenia patients: amphetamine within-subject dose response and time course
Valk et al. Failure of introduction of cashew nut after a negative oral food challenge test in children.
Jones et al. Impact of inflammatory bowel disease and high-dose steroid exposure on pupillary responses to negative information in pediatric depression
Cramer Tolerability of antiepileptic drugs: can we determine differences?
HK40067853A (en) Methods for improving the quality of life of a patient with a peanut allergy
You et al. Clinical experience with sesame oral immunotherapy and a quality-of-life assessment
Melles et al. Anxiety matters: food exposure, weight exposure, and virtual body exposure in anorexia nervosa
Scheffers et al. Health-Related Quality of Life and Fatigue in Children with Pompe Disease
Movahedi et al. Oral Immunotherapy with the Rush Method in Patients with Egg White Allergy: A Randomized, Double Blind, Clinical Trial

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER APPLICANT(S): AIMMUNE THERAPEUTICS, INC.